This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion. Information in this statewide guideline is current at the time of publication. SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links. Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation. If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline. This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:
Fetal wellbeing  Women with cyanotic heart disease, NYHA III or IV, left heart obstruction, smokers, multiple gestation, beta-blocker use and anticoagulation are at high risk of having a fetus with growth restriction. These women should be offered regular ultrasound assessments of fetal wellbeing (growth, umbilical artery Doppler, AFI) and cardiotocography in the third trimester
Fetal risks
 Fetal cardiac assessment is necessary because there is a 2 to 16 % risk of congenital heart disease in the fetus in pregnant woman with structural congenital heart disease 7 . The incidence of congenital heart disease in the offspring is more common in the fetus when the mother, rather than the father, is affected, particularly if the mother has a condition such as bicuspid aortic valve, which is more common in the male  Autosomal dominant conditions such as Marfan's syndrome, hypertrophic cardiomyopathy, mitral valve prolapse and channelopathies have a 50 % chance of being passed on, but may not be associated with any structural abnormalities in the fetus  Early diagnosis of congenital heart defect in the fetus (before 24 weeks of gestation) allows the possibility of termination of the pregnancy (TOP)
 Affected fetuses benefit from delivery in a tertiary care centre (Level 5, 6) with Paediatric Cardiac Support  The two main determinants of fetal prognosis are maternal functional class and the degree of maternal cyanosis. When the mother is in functional class III to IV, or has a high risk disease such as severe aortic stenosis or Eisenmenger syndrome or is cyanosed, monitoring of fetal growth is very important 7  In Australia and New Zealand, neonatal survival ranges from 69 % at 24 weeks gestation to 93 % at 27 weeks gestation. The risk of cerebral palsy in surviving neonates at < 28 weeks gestation is 9.1 %, varying from 7% to 15 % (27 to 24 weeks gestation). Of the overall 9.1 %, 27 % have grade 1 cerebral palsy (on a grading scale of 1 to 5) 8  Therefore, when cardiac function is reduced to critical levels, surgery or percutaneous procedures to improve maternal cardiac function should be undertaken, if feasible, in order to postpone delivery as long as possible 7  The choice between corrective procedures and delivery may be difficult between 28 and 32 weeks, and decisions must be individualised  Administer IM betamethasone in two doses of 11.4 mg (5.7 mg x 2) 24 hours apart to the woman if birth is likely to occur between 23 +0 and 35 +0 weeks
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Level of hospital care (see Flowchart 1 and Table 1)  Echocardiographic assessment results and the on-going NYHA functional classification will determine if the level of hospital care required is:  The majority of women with arrhythmias during pregnancy have a benign increased rate of atrial or ventricular premature beats 9 . Both ectopic beats and sustained arrhythmias become more frequent during pregnancy. They may even develop for the first time. In general they are treated in the same way as non-pregnant patients, but as conservatively as possible. Definitive treatment is reserved for the postpartum period if it is safe to do so. Women who are worried about ectopic beats can usually be reassured unless the frequency increases on exercise  Haemodynamically stable women do not usually require treatment  Advise woman to avoid precipitating factors such as caffeine, alcohol, tobacco, fatigue and anxiety
Other arrhythmias  Women with more ominous atrial arrhythmias (supraventricular tachycardia, atrial fibrillation and flutter) should be managed in collaboration with a cardiologist, usually using the same agents that would be chosen in the non-pregnant woman, including electrical cardioversion when necessary 9  All commonly used anti-arrhythmic drugs cross the placenta. The pharmacokinetics of drugs are altered in pregnancy and require close clinical monitoring to ensure maximum efficacy and avoid toxicity  Supraventricular tachycardias are corrected by vagal stimulation or, failing that, intravenous adenosine. If adenosine is unsuccessful at restoring sinus rhythm consider using β-blockers or verapamil. Electrical cardioversion is not contraindicated and should be used for any sustained tachycardia causing haemodynamic instability and therefore threatening fetal wellbeing. Beta blocking drugs with beta-1 selectivity are the first choice for prophylaxis. Verapamil is constipating but may be used if there is a contraindication to β-blocker use (such as asthma)
 Both β-blockers and the dihydropyridone calcium antagonists can cause fetal bradycardia. If the arrhythmia is uncontrolled and severely compromising the health of the mother and fetus, radio frequency ablation for atrio ventricular (AV) nodal re-entry or certain atrio ventricular re-entry tachycardias can, if necessary, be performed during pregnancy with suitable lead shielding and maximal use of echo rather than X-ray fluoroscopy  Class I agents such as flecainide may be considered if the maternal left ventricle is normal. Information on its use in pregnancy is limited. Of the Class III agents, sotalol is much more preferable to amiodarone and has similar risks to β-blockers with the increased risk of torsdae de pointes due to QT prolongation. Amiodarone should be avoided unless the maternal arrhythmia is life-threatening to the mother or fetus, other agents have failed and the arrhythmia is not manageable with radiofrequency (RF) ablation. Long term use of amiodarone can cause neonatal hypothyroidism (9 % of newborns), hyperthyroidism, and goitre  Potentially life-threatening ventricular tachyarrhythmias are much less common and should be terminated by electrical cardioversion if causing maternal haemodynamic compromise. Management requires the opinion of a cardiologist and should be managed as in the non-pregnant woman. This includes the use of antiarrhythmic medication in the shortto long-term and / or the likely insertion of an automatic internal cardiac defibrillator (ICD)
Pacemakers and automatic internal cardiac defibrillators (ICD)
 The presence of a pacemaker or an ICD does not itself contraindicate pregnancy. The presence of any underlying structural heart disease determines the risk of pregnancy  Pregnancy in patients with an ICD does not cause increased ICD-related complications or adverse events in the mother or fetus; neither does it increase the number of ICD discharges  A pacemaker for the alleviation of symptomatic bradycardia, or ICD can be implanted at any stage of pregnancy using X-ray fluoroscopy with suitable lead shielding and echo guidance, to minimise the radiation dose delivered to the mother and fetus  Any woman with an ICD should be advised to carry identification information about the ICD type, date implanted, and location of implantation in her South Australian pregnancy record. A plan for deactivation in case of an emergency should be documented in her South Australian pregnancy record.
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 The presence of a pacemaker or ICD should not alter the mode of delivery. This is determined by obstetric indications  If Caesarean section is required, the ICD should be temporarily inactivated (preferably by reprogramming or in an emergency by application of a magnet over the generator) until the procedure is finished. While inactivated, the patient should have continuous ECG monitoring and external defibrillation available at all times Rheumatic heart disease and mitral stenosis  The incidence of rheumatic heart disease is decreasing in developed countries. Mitral stenosis is the most common sequelae  RDH Registry in SA: email rhd@sa.gov.au; Ph (08) 7425 7146
 In women with rheumatic heart disease, the mitral valve is most commonly affected. Mitral stenosis occurs in 90 % of cases, mitral regurgitation in 7 %, aortic regurgitation 2.5 % and aortic stenosis in 1 % of cases of rheumatic heart disease10
Mitral stenosis
 Women with mild (NYHA class I) mitral stenosis may be asymptomatic until pregnancy -the increase in left atrial pressure may lead to subsequent symptoms of dyspnoea, and eventually tachypnoea, orthopnoea, and paroxysmal nocturnal dyspnoea  Manage according to symptoms and with the guidance of echocardiography, which is the key to the assessment of valvular severity. Mitral stenosis is considered severe and associated with significant increased maternal and fetal risk when the mitral valve area is estimated to be < 1.5 cm 2 , the functional capacity is NYHA III or IV or the right heart pressures rise significantly (estimated PA systolic pressure > 50 mmHg or > 75 % of the systemic pressure)
Medical treatment
 Limitation of exercise, fluid and salt restriction should be used when the functional class is NHYA II or more  In cases of poor functional tolerance, consider oral β-adrenergic blockers (decreases maternal tachycardia), and judicious use of diuretics, avoiding vigorous volume depletion to protect against uteroplacental hypoperfusion (caution in women with severe mitral stenosis -may need concurrent use of invasive haemodynamic monitoring) 10  Aggressively cardiovert new onset atrial fibrillation back to sinus rhythm with β-blockers, verapamil and / or direct current (DC) cardioversion (see above)
 Consider digoxin to control the ventricular response to chronic atrial fibrillation.
 See anticoagulation prophylaxis for treatment recommendations

Intervention
 Women who fail medical treatment during pregnancy with repeated episodes or persistent heart failure should be considered for percutaneous mitral valvotomy if suitable anatomy is present. After successful mitral valvotomy, pregnancy can often continue successfully to term  Surgical replacement of the mitral valve is used as a last resort with high fetal risk of perioperative death. If possible, this should be delayed until the fetus is viable and can be delivered before the surgical intervention Intrapartum  The mode of delivery is determined by obstetric indications only  Care in tertiary centre for NYHA functional class I, II. These patients can be managed in the delivery suite without invasive monitoring. ECG monitoring to monitor maternal heart rate would be preferable  NYHA functional class III, IV: Refer to hospital with specialist adult cardiac service and invasive monitoring in labour. These patients should be managed in an intensive care setting with invasive monitoring, avoiding haemodynamic stress and having careful control of heart rate. Tachycardia can be prevented with intravenous esmolol as necessary There is an association with bicuspid aortic valve and aortic root dilatation and co-arctation  May also be associated with mitral stenosis if the aetiology is rheumatic fever  Maternal mortality associated with severe aortic stenosis is 17 % with a fetal mortality of 32 %
10
 Echocardiography is essential in determining the severity of the stenosis. In pregnancy an aortic valve area < 1.0 cm 2 (0.6 cm 2 / m 2 BSA) is associated with a significant increased maternal and fetal risk  Decisions regarding anaesthesia and mode of delivery must be individualised on the basis of obstetric indications, severity of maternal symptoms and aortic valve area  In severe or symptomatic aortic stenosis, the intrapartum management should be carried out in a hospital with adult cardiac services and an adult intensive care. Invasive monitoring, especially intra-arterial pressure monitoring is of utmost importance. Avoidance of hypotension and hypovolaemia is essential to avoid haemodynamic collapse  Balloon aortic valvuloplasty (BAV) is a good option for severe aortic stenosis (usually preferred to be performed in 2nd trimester) to provide assistance in managing symptoms in pregnancy, defer definitive valve surgery and is low risk to mother and fetus  Despite aggressive medical therapy, some women will require aortic valve replacement in pregnancy. Case reports suggest that pulsatile perfusion at bypass may help preserve placental haemodynamic function 10 
Aortic regurgitation
 May also be associated with mitral stenosis  Clinical course is determined more by the extent of their mitral valve disease than by their aortic regurgitation  When aortic regurgitation is the predominant lesion, pregnancy is usually well tolerated and may improve in pregnancy due to the decrease in systemic vascular resistance  Cardiac surgery for aortic regurgitation (valve replacement) is high risk to mother and fetus and can usually be deferred until after delivery (aortic regurgitation is well tolerated in pregnancy)
 Also, the physiologic tachycardia of pregnancy may reduce regurgitant flow as diastolic filling times are shortened  Murmurs normally associated with both aortic and mitral regurgitation may be reduced in pregnancy  Women with severe aortic regurgitation and symptoms of left-sided heart failure should decrease their physical activity  Reduce sodium intake < 2 g per day
 Consider diuresis or vasodilators (e.g. hydralazine or nifedipine) and inotropic therapy in difficult cases
Congenital heart disease  May be organised into acyanotic and cyanotic types  Acyanotic congenital heart lesions include: 
Coarctation of the aorta
 Coarctation of the aorta should be repaired before pregnancy. It is rare during pregnancy (9 % of all congenital defects). The management of hypertension is difficult in the unoperated pregnant woman. Fetal growth is usually normal and in contrast to essential hypertension, there is not an increased incidence of preeclampsia. Over enthusiastic treatment may cause hypotension in the distal segment. This may result in abortion or fetal death even though pressure in the proximal segment continues to rise on effort  Rupture of the aorta is the most common reported cause of death, and rupture of an aneurysm of the circle of Willis has also been reported during pregnancy. The increase in blood volume and cardiac output increases the risk of aortic dissection or rupture during pregnancy and a beta blocker should be prescribed  Restriction of physical activity is the only way of minimising potentially dangerous surges in blood pressure  Surgical correction is only very rarely indicated during pregnancy if systolic hypertension is uncontrolled or heart failure is present  Balloon angioplasty is contraindicated because of the risk of dissection or rupture. Whether this risk is avoidable with stenting is not known
Marfan syndrome
 Rare -incidence is 1 in 5,000 7, 11  Women with a documented aortic root diameter of < 40 mm without an abnormal aortic valve have a mortality rate of < 5 %  Risk of aortic dissection during pregnancy or shortly thereafter is approximately 10 % with the incidence appearing to increase with increasing aortic root diameter 7  Aortic or mitral regurgitation is also seen in 60 % of women with Marfan syndrome and may complicate pregnancy 11  Regular echocardiography before, during and after pregnancy to monitor aortic root size and valvular function  Genetic testing through chorionic villus biopsy, amniocentesis cell culture or postnatal testing  Angiotensin receptor blockers are recommended before pregnancy to decrease increasing aortic root dilatation but must be stopped during pregnancy  Β-blockers are strongly recommended before and during pregnancy to decrease the risk of aortic dilatation and dissection  Pregnancies complicated by Marfan syndrome are not associated with poor perinatal outcomes, though some suggest there is an increased risk of incompetent cervix  Physical, echocardiographic, and ophthalmologic examination of newborns  Counsel woman regarding the risk of autosomal dominant inheritance and need for followup for their offspring 11 
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Intraatrial repair for transposition of great arteries (TGA) 
Warfarin
 Warfarin crosses the placenta, is teratogenic and may cause haemorrhage in the fetus  The teratogenic effects appear to result from inhibition of vitamin K and / or arylsulphatase E activity during skeletal development  The fetal warfarin syndrome comprises nasal hypoplasia, short fingers with hypoplastic nails, low birth weight, stippling of epiphyses on X-ray and intellectual disability  Recent estimates indicate the risk of fetal warfarin syndrome in babies of women who require warfarin throughout pregnancy is around 5 % with the risk increasing with higher doses of warfarin  The period of greatest embryonic susceptibility is between 6 and 9 weeks of gestation. It is recommended that, wherever possible, the drug is avoided throughout the first trimester 14 Pulmonary hypertension  Rare in pregnancy -women with pulmonary hypertension have a high morbidity and mortality during pregnancy e.g. right heart failure, pulmonary thromboembolism, sudden death 16  Existing pulmonary vascular disease prevents the fall in pulmonary vascular resistance, leading to a rise in pulmonary artery pressure with increased cardiac output. Ultimately, the increase in cardiac output cannot be achieved resulting in right heart failure 16  When pregnancy occurs and termination is declined, or pulmonary hypertension is newly diagnosed during pregnancy, management must be by the multidisciplinary team, including a pulmonary hypertension specialist, in a Level 6 tertiary centre with Adult ICU 16  Women with Eisenmenger syndrome are at particular risk of increased right-to-left shunting. Hypoxia can lead to syncope and sudden death Ischaemic heart disease  Includes acute myocardial infarction (MI), unstable angina, stable angina  Requires care in a tertiary centre or care in a tertiary centre with specialist adult cardiac service care depending on echocardiograph findings and symptoms according to NYHA functional classification  Rare in pregnancy -ischaemic heart disease occurs on average in 1 in 10,000 deliveries  Myocardial infarction (MI) in pregnancy occurs on average in 7.5 in 100,000 deliveries with mortality highest in the third trimester in women under 35 years of age Heart failure and cardiomyopathy  Includes left sided, right heart failure and biventricular heart failure  Common causes for heart failure in the puerperium include iatrogenic fluid therapy overload, pre-eclampsia, thyrotoxicosis, peri-partum cardiomyopathy, anaemia or previously undiagnosed rheumatic or congenital heart disease Cardiac conditions associated with high maternal and / or fetal risk during pregnancy (See Table 1 be used by these women, as the thromboembolic risk of oral contraceptives is thought to be due to the oestrogen component.
 The progestin-releasing intrauterine contraceptive device (IUCD) has a failure rate of < 1 % and in a monogamous couple the risk of endocarditis associated with the use of an IUCD is rare. Prophylaxis with oral amoxicillin (2 g taken one hour before insertion or removal) is recommended
Follow-up
 Postnatal follow up should be at a high risk medical clinic and with the woman's cardiologist
